India is the largest producer and exporter of Hydroxychloroquine with 70 per cent of annual global production. Department of Pharmaceuticals has said that there is enough stock of API and manufacturing capacity of Hydroxychloroquine formulations to meet country’s requirement as well as export obligations.
Meanwhile, Senior Scientist at ICMR Dr Raman Gangakhedkar told media in New Delhi today that the use of Hydroxychloroquine is as prophylaxis and not as treatment. He said, the medicine was never recommended for general public for the treatment of COVID-19.
Discussion about this post